Developments in parathyroid hormone and related peptides as bone-formation agents

Area of Science:

• Endocrinology
• Bone Biology
• Pharmacology

Background:

• Osteoporosis is a significant global health issue.
• Parathyroid hormone (PTH) and its analogs are potent anabolic agents for bone formation.
• Teriparatide (recombinant human PTH(1-34)) is a leading osteoporosis treatment, despite potential risks.

Purpose of the Study:

• To differentiate the biological activities of N-terminal and C-terminal regions of parathyroid hormone (PTH).
• To understand the distinct mechanisms of PTH fragments and analogs in bone remodeling.
• To evaluate the role of PTH's C-terminal region in bone-cell apoptosis and turnover.

Main Methods:

• Review of existing literature on parathyroid hormone (PTH) and its fragments.
• Analysis of the distinct biological activities mediated by N-terminal and C-terminal PTH regions.
• Comparison of the effects of teriparatide with native PTH and other fragments.

Main Results:

• N-terminal PTH fragments and analogs, like teriparatide, promote bone formation.
• The C-terminal region of PTH, acting via a separate receptor, induces bone-cell apoptosis.
• PTH's C-terminal activity may counteract the anti-apoptotic effects of teriparatide, influencing bone turnover.

Conclusions:

• Native PTH, its N-terminal fragments, and analogs exhibit varied activities.
• The distinct actions of different PTH regions necessitate separate therapeutic considerations.
• Understanding these differences is crucial for developing safe and effective osteoporosis treatments.